478 related articles for article (PubMed ID: 17254569)
1. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
2. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
4. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein.
Marxreiter F; Nuber S; Kandasamy M; Klucken J; Aigner R; Burgmayer R; Couillard-Despres S; Riess O; Winkler J; Winner B
Eur J Neurosci; 2009 Mar; 29(5):879-90. PubMed ID: 19291219
[TBL] [Abstract][Full Text] [Related]
5. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
6. Embryonic stem cell-derived neuron models of Parkinson's disease exhibit delayed neuronal death.
Yamashita H; Nakamura T; Takahashi T; Nagano Y; Hiji M; Hirabayashi T; Amano T; Yagi T; Sakai N; Kohriyama T; Matsumoto M
J Neurochem; 2006 Jul; 98(1):45-56. PubMed ID: 16805795
[TBL] [Abstract][Full Text] [Related]
7. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
9. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
10. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.
Chiba-Falek O; Lopez GJ; Nussbaum RL
Mov Disord; 2006 Oct; 21(10):1703-8. PubMed ID: 16795004
[TBL] [Abstract][Full Text] [Related]
11. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.
De Lella Ezcurra AL; Chertoff M; Ferrari C; Graciarena M; Pitossi F
Neurobiol Dis; 2010 Mar; 37(3):630-40. PubMed ID: 19969084
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
13. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra.
von Bohlen und Halbach O; Minichiello L; Unsicker K
FASEB J; 2005 Oct; 19(12):1740-2. PubMed ID: 16037097
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
[TBL] [Abstract][Full Text] [Related]
16. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
[TBL] [Abstract][Full Text] [Related]
18. Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors.
Krenz A; Falkenburger BH; Gerhardt E; Drinkut A; Schulz JB
J Neurochem; 2009 Jan; 108(1):139-46. PubMed ID: 19094062
[TBL] [Abstract][Full Text] [Related]
19. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M
Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
